While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Brookstone Capital Management trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.9% in the fourth ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Wedmont Private Capital lessened its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 17.7% in the fourth ...
Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The ...
We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...
Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer PFE we detected 12 trades. If we consider the specifics of each trade, it is ...
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
Hosted on MSN23h
This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.There has been a shakeup in markets since Donald Trump’s election, and investors have been positioning their portfolios to ...
Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback